New First-In-Class Treatment Fycompa® [black triangle drug] Launches Today for Most Common Form of Epilepsy

New First-In-Class Treatment Fycompa® [black triangle drug] Launches Today for Most Common Form of Epilepsy PR Newswire HATFIELD, England, September 13, 2012 HATFIELD, England, September 13, 2012 /PRNewswire/ -- UK first country in Europe to gain access to new therapy for partial epilepsy ®Fycompa ▼ (perampanel), discovered and developed by Eisai in the UK and Japan, is launched today as the first in an entirely new class of treatment for uncontrolled partial epilepsy (the most common form of the condition). The new therapy has demonstrated efficacy in partial onset seizures, in particular with secondary generalisations. It is indicated as an adjunctive treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy [1]aged 12 years and older. The worldwide supply of this new drug will be manufactured, packaged and distributed from the company's new £100 million facility in Hatfield, Hertfordshire. Perampanel is the first and only licensed anti-epileptic drug (AED) to selectively target AMPA receptors, a receptor in the [2]brain which plays a critical role in the spread of epileptic seizures. This mechanism of action is different to other, [1]currently available AEDs. In addition, perampanel has the added benefit of convenient, once-daily dosing at bedtime and significantly, is the only third generation partial epilepsy treatment approved to treat adolescents with epilepsy from launch.